How does GE’s third CEO in three years write about the company—which is breaking itself apart—to shareholders? Briefly.
Larry Culp’s first shareholder letter as General Electric Co.’s CEO was relatively brief and deployed less frequently some words and phrases that longtime leader Jeff Immelt often used to define the goals of the once-sprawling conglomerate.
The shorter missive reflects changes in GE itself, which has had three CEOs in three years, can only afford to pay a token dividend and is breaking itself apart. The company lost some $200 billion in market value over two years and was dropped from the Dow Jones Industrial Average last...
Malaysia Latest News, Malaysia Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
GE CEO says company needs to reduce debt 'thoughtfully and soon'General Electric Co has too much debt and needs to reduce it 'thoughtfully ...
Read more »
Widely followed analyst Tusa says GE report shows 'material and negative' disclosuresGeneral Electric's latest annual update to shareholders justifies a below-consensus view on profit, according to J.P. Morgan's Stephen Tusa.
Read more »
Cramer Remix: GE's CEO has breathed new life into a fallen franchiseJim Cramer breaks down how General Electric has transformed with Larry Culp at the helm.
Read more »
GE to Sell BioPharma Business to Danaher for $21.4 BillionGeneral Electric to sell biopharma unit to Danaher for $21.4 billion, part of a strategy to reduce leverage and boost its balance sheet
Read more »
GE withdraws plans for Healthcare IPO after Danaher deal: BloombergGeneral Electric will no longer seek an IPO for its health-care unit following the sale of its biopharma business, CEO Larry Culp told Bloomberg on Monday.
Read more »
GE shares surge 13% after Danaher agrees to buy biopharma business for $21.4 billionGE is selling its biopharma unit for $21.4 billion to Danaher, saying it will use the money to reduce leverage and strengthen its balance sheet.
Read more »
GE stock rockets after $21 billion deal with Danaher, but remains below key chart levelShares of General Electric Co. rocket after a deal to sell the company’s biopharma business for $21.4 billion in cash to Danaher Corp, but remain on track to extend their longest streak below the widely watched 200-day moving average in at least 40 years.
Read more »
GE-Danaher pharma deal is a win-win remedyCEO Larry Culp is unloading the conglomerate’s biologics unit to his old employer for $21 bln. It’s his boldest downsizing move yet and will help cut leverage. Danaher gains scale in its health business at a reasonable price while Culp needed a sale, not necessarily top dollar.
Read more »
GE shares rise as analysts say annual report reveals a major issue is 'likely contained'Wall Street analysts said GE's 'more detailed' disclosure of insurance liabilities shows less risk than last year.
Read more »